Surgical Oncology GI Update

Papers that have been accepted for publication in 2010:

Frolov A, Liles JS, Kossenkov AV, Tzeng CW, Kulesza, P, Jhala N, Varadarajulu S, Eloubeidi M, Heslin MJ, Arnoletti JP. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am J Surg. 2010 Apr 19.

Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2010 Jun 30.

Capo-chichi CD, Smedberg JL, Rula ML, Nicolas E, Yeung A, Adamo RF, Frolov A, Godwin AK, Xu XX, Alteration of differentiation potentials by modulating GATA transcription factors in murine embryonic stem cells. Stem Cells International, 2010 (11):602068.

Liles JS, Arnoletti JP, Tzeng C-W, Howard JH, Kossenkov AV, Kulesza P, Heslin MJ, Frolov A. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biology and Therapy, 2010. Sep;10(6):555-63.

Oral presentations to be presented at our National meeting in March 2011:

Frolov A., Liles S, Azih L, Mikhailina A, Arnoletti JP. ErbB3 targeting with MM-121 monoclonal antibody, inhibits tumorigenesis in a murine model of human pancreatic adenocarcinoma. Society of Surgical Oncology 64th Annual Cancer Symposium, San Antonio, TX, March 5, 2011.

Abstracts that were accepted and/or presented in 2010:

Arnoletti, JP; Frolov, A; Eloubeidi, M; Posey, J; Keene, K; Jhala, N; Oster, R; Christein, J; Buchsbaum, D; Vickers, S. A phase I study Evaluating the role of cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. 9th World Congress of the IHPBA Buenos Aires, April 18-22, 2010.

Liles S, Frolov A, Frost A, Kulesza P, Heslin MJ, Arnoletti JP. Pancreatic Cancer-Associated Fibroblasts and ErbB3-mediated Tumorigenesis. Society of Surgical Oncology Annual Meeting. Chicago, 2010.

Allen, D., Arnoletti, JP., Heslin, M., Taguchi, T., Kashentseva, E., Dmitriev, I., Frolov, A. Gastrointestinal Stromal Tumors (GIST) cell proliferation inhibition with combined adenoviral and molecular targeted therapy. Society of Surgical Oncology Annual Meeting. Chicago, 2010.

Allen, D., Arnoletti, JP., Heslin, M., Taguchi, T., Kashentseva, E., Dmitriev, I., Frolov, A. Gastrointestinal stromal tumors (GIST) cell proliferation inhibition with combined adenoviral and molecular targeted therapy. AACR annual meeting. Washington, DC, 2010.

Residents who are training to be Surgeon Scientists:

Spenser Liles, MD Surgical Research Fellow (support: T32 NRSA/NIH grant) University of Alabama at Birmingham, Birmingham, AL (Finished 6/31/2010)

Derron Allen, MD; Postdoctoral fellow (Support: T32 NRSA/NIH grant) (Finished 6/31/2010)

Lilian Azih, MD; Surgical Research Fellow (Support: T32 NRSA/NIH grant) University of Alabama at Birmingham, Birmingham, AL (started 7/1/2010

Grants and Contracts that were achieved in 2010:

“Pre-clinical studies of anti-ErbB3 antibody (MM-121) in pancreatic ductal adenocarcinoma.” Merrimack Pharmaceutical, Inc. contract agreement PI. Frolov, A., $176,000 for three year project (one third each year).

NIH, SPORE pilot project (2P50CA101955) “Dual targeting of EGFR and ErbB3 in pancreatic cancer treatment.” PI, Frolov, A., $55,000 for one year project.

Susan Mott Webb Charitable Trust, $15,000, assisted with purchase of Olympic BX41 Microscope.